I see these as positive appointments which bolster the management team at a key time. Why don't you back up your slanderous accusations with some facts? Or are you only good at posting baseless, self-serving opinions?
About Tillotson's prior company's Replidyne: failed company due to unsuccessful development/NDA and FDA warning letters for non compliance of the trials Oscient: Failed company, even though it spent hundred millions on a commercial sales force for antibiotic Factive
Gorbach: formally OPTR's CMO, before that a physician at A University...No training in development nor R&D, no Pharm. Dev experience...zilch!
Lesnick: don't even get me started...LOL. Look at his very limited background
Buy and hold ( or should it be buy and lose) why dont you provide evidence as to why this is bolstering? Very weak management...but that just on par with the value of their product and lack of pipeline....foolish Lings indeed
What did you think of today's price action? I would of thought more buyers would have come in after the CNBC interview.Would of liked to seen the stock up 5% today.Hopefully tomorrow will be a green day.GLTA